teaser
Dexrazoxane (Cardioxane®) has been launched in the UK for the prevention of chronic cumulative cardiotoxicity caused by doxorubicin or epirubicin in advanced and/or metastatic cancer patients after previous anthracycline-containing treatment. The drug is administered by a short intravenous infusion approximately 30 minutes before anthracycline administration at a dose equal to 20 times the doxorubicin and 10 times the epirubicin-equivalent dose; this equates to a dose of 1,000mg/m2 when the commonly used dosage schedule for doxorubicin of 50mg/m2 or epirubicin 100mg/m2 is employed.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
PharmaTimes 3/8/2007
